Treatment of Intracranial Hypertension: New Options or Not?

Update Item Information
Identifier 20210221_nanos_journalclub1_06-abstract
Title Treatment of Intracranial Hypertension: New Options or Not?
Creator Julie Falardeau, MD
Affiliation Oregon Health and Science University, Portland, OR
Subject Diopathic Intracranial Hypertension; Weight Loss; Carbonic Anhydrase Inhibitor; Glucagon-like Peptide 1 Receptor Agonist; 11b-hydroxysteroid Dehydrogenase Type 1
Description Idiopathic intracranial hypertension (IIH) is characterized by elevation of intracranial pressure (ICP) without; an identifiable cause. Over the years, a number of varied treatments have been suggested with the; ultimate goals to preserve vision and alleviate symptoms, especially headache. There are currently no; established guidelines to standardize the treatment of IIH. In 2015, the Cochrane review concluded that; there is insufficient evidence on the best therapeutic strategies. Traditionally, the treatment of IIH has; included weight loss, medications, and surgical interventions when rapid or progressive vision loss occurs; despite optimal medical therapy.
Date 2021-02
Language eng
Format application/pdf
Type Text
Source 2021 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS Annual Meeting 2021: Journal Club: What You Need to Know Now!
Collection Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/
Publisher North American Neuro-Ophthalmology Society
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management Copyright 2021. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6sj7jdt
Setname ehsl_novel_nam
ID 1694263
Reference URL https://collections.lib.utah.edu/ark:/87278/s6sj7jdt